4basebio PLC (LSE:4BB), the synthetic DNA specialist, has delivered a steady stream of announcements over recent months, keeping it on the radar of investors following life sciences names on the FTSE AIM All Share Index. The latest news came on 28 September 2026, when the company announced a Partnership with TriLink BioTechnologies to advance a leading pharmaceutical company's Phase I cell therapy programme. That followed a strategic collaboration with Genezen announced in late August and the publication of its half-year report.

Together, these updates suggest a company moving from platform development towards commercial relationships with established players in advanced therapies.

What 4basebio Does

4basebio develops and manufactures synthetic, cell-free DNA for use in gene therapies, cell therapies, genetic vaccines and related applications. Traditional DNA production for these markets has relied heavily on plasmid DNA grown in bacteria, a process that can be slow and may introduce unwanted bacterial sequences. Synthetic, enzymatically produced DNA is intended to offer faster production, greater purity and more flexible design.

The company supplies material for research use only (RUO) as well as higher-quality grades intended to support clinical work, and it has been building partnerships with manufacturers and developers across the advanced therapy Supply chain.

Latest Developments

On 31 March 2026, 4basebio announced what it called a major expansion, leasing an innovation hub and Manufacturing Facility in Cambridge, UK, to support growing Demand for its RUO and high-quality synthetic DNA. In August 2026, it entered into a strategic collaboration and Marketing agreement with Genezen to advance synthetic, cell-free DNA platforms for next-generation viral vector manufacturing. Viral vectors are a key delivery mechanism in many gene therapies.

The September agreement with TriLink BioTechnologies, a supplier of mRNA and nucleic acid products, links the company to a Phase I cell therapy programme run by an unnamed leading pharmaceutical group. Earlier in the year, 4basebio presented at Biotech Showcase 2026, a major investor conference for the sector.

Financial Picture

The company's most recent full-year results showed Revenue surging in what was characterised as a step-change year. The company has since published its half-year report for 2026. Specific revenue, loss and cash figures from these reports were not available at the time of writing, and readers may wish to refer to the original announcements for the detailed numbers.

As a growth-stage biotechnology Business investing in manufacturing capacity, 4basebio is not a Dividend payer, and its spending on facilities and development means funding and cash runway are important considerations.

Sector and index Context

The cell and gene therapy sector has had a mixed period, with solid scientific progress offset by tighter funding conditions for many developers. Suppliers of critical materials, such as DNA templates, stand to benefit if therapies move through Clinical Trials into commercial production. Within the FTSE AIM All Share Index, 4basebio sits among a group of smaller healthcare and biotechnology companies whose share prices can be sensitive to individual commercial announcements.

Key Risks

The main risks include the pace of customer adoption of synthetic DNA over established plasmid methods, dependence on the progress of partners' clinical programmes, the cost of scaling manufacturing, competition from other DNA producers, and the potential need for further funding. Regulatory requirements for clinical-grade material add further complexity.

What to Watch Next

Investors will be watching for progress at the new Cambridge facility, further commercial agreements, and evidence that partnerships such as those with Genezen and TriLink translate into recurring revenue. Updates on clinical programmes using 4basebio's DNA, and the next full-year results, will be key milestones.